| 000 | 01600 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250517151247.0 | ||
| 264 | 0 | _c20170809 | |
| 008 | 201708s 0 0 eng d | ||
| 022 | _a1532-1967 | ||
| 024 | 7 |
_a10.1016/j.ctrv.2017.03.006 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMok, Tony S K | |
| 245 | 0 | 0 |
_aThe accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. _h[electronic resource] |
| 260 |
_bCancer treatment reviews _cApr 2017 |
||
| 300 |
_a181-189 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAminopyridines |
| 650 | 0 | 4 | _aAnaplastic Lymphoma Kinase |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aCarbazoles _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLactams |
| 650 | 0 | 4 |
_aLactams, Macrocyclic _xtherapeutic use |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aOrganophosphorus Compounds _xtherapeutic use |
| 650 | 0 | 4 |
_aPiperidines _xtherapeutic use |
| 650 | 0 | 4 | _aPyrazoles |
| 650 | 0 | 4 |
_aPyrimidines _xadverse effects |
| 650 | 0 | 4 |
_aReceptor Protein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aSulfones _xadverse effects |
| 700 | 1 | _aCrino, Lucio | |
| 700 | 1 | _aFelip, Enriqueta | |
| 700 | 1 | _aSalgia, Ravi | |
| 700 | 1 | _aDe Pas, Tommaso | |
| 700 | 1 | _aTan, Daniel S W | |
| 700 | 1 | _aChow, Laura Q M | |
| 773 | 0 |
_tCancer treatment reviews _gvol. 55 _gp. 181-189 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ctrv.2017.03.006 _zAvailable from publisher's website |
| 999 |
_c27097888 _d27097888 |
||